Literature DB >> 10087018

Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.

J P McLaughlin1, K P Hill, Q Jiang, A Sebastian, S Archer, J M Bidlack.   

Abstract

Two 14beta-p-nitrocinnamoyl derivatives of dihydrocodeinone, 14beta-(p-nitrocinnamoylamino)-7,8-dihydrocodeinone (CACO) and N-cyclopropylmethylnor-14beta-(p-nitrocinnamoylamino)- 7, 8-dihydrocodeinone (N-CPM-CACO), and the corresponding chlorocinnamoylamino analogs, 14beta-(p-chlorocinnamoylamino)-7, 8-dihydrocodeinone (CAM) and N-cyclopropylmethylnor-14beta-(p-chlorocinnamoylamino) -7, 8-dihydrocodeinone (MC-CAM), were tested in opioid receptor binding assays and the mouse tail-flick test to characterize the opioid affinity, selectivity, and antinociceptive properties of these compounds. In competition binding assays, all four compounds bound to the mu opioid receptor with high affinity. When bovine striatal membranes were incubated with any of the four dihydrocodeinones, binding to the mu receptor was inhibited in a concentration-dependent, wash-resistant manner. Saturation binding experiments demonstrated that the wash-resistant inhibition of mu binding was due to a decrease in the Bmax value for the binding of the mu-selective peptide [3H][D-Ala2, MePhe4,Gly(ol)5] enkephalin and not a change in the Kd value, suggesting an irreversible interaction of the compounds with the mu receptor. In the mouse 55 degrees C warm water tail-flick test, both CACO and N-CPM-CACO acted as short-term mu-selective agonists when administered by i. c.v. injection, whereas CAM and MC-CAM produced no measurable antinociception at doses up to 30 nmol. Pretreatment of mice for 24 h with any of the four dihydrocodeinone derivatives produced a dose-dependent antagonism of antinociception mediated by the mu but not the delta or kappa receptors. Long-term antagonism of morphine-induced antinociception lasted for at least 48 h after i.c. v. administration. Finally, shifts in the morphine dose-response lines after 24-h pretreatment with the four dihydrocodeinone compounds suggest that the nitrocinnamoylamino derivatives may produce a greater magnitude long-term antagonism of morphine-induced antinociception than the chlorocinnamoylamino analogs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10087018

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

1.  Reinstatement of cocaine place-conditioning prevented by the peptide kappa-opioid receptor antagonist arodyn.

Authors:  A N Carey; K Borozny; J V Aldrich; J P McLaughlin
Journal:  Eur J Pharmacol       Date:  2007-05-13       Impact factor: 4.432

2.  Nonpeptide small molecule agonist and antagonist original leads for neuropeptide FF1 and FF2 receptors.

Authors:  V Blair Journigan; Christophe Mésangeau; Neha Vyas; Shainnel O Eans; Stephen J Cutler; Jay P McLaughlin; Catherine Mollereau; Christopher R McCurdy
Journal:  J Med Chem       Date:  2014-10-21       Impact factor: 7.446

3.  Novel opioid cyclic tetrapeptides: Trp isomers of CJ-15,208 exhibit distinct opioid receptor agonism and short-acting κ opioid receptor antagonism.

Authors:  Nicolette C Ross; Kate J Reilley; Thomas F Murray; Jane V Aldrich; Jay P McLaughlin
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

4.  Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones.

Authors:  Nick P R Nieland; Humphrey A Moynihan; Simon Carrington; Jillian Broadbear; James H Woods; John R Traynor; Stephen M Husbands; John W Lewis
Journal:  J Med Chem       Date:  2006-08-24       Impact factor: 7.446

5.  Peptides derived from the prohormone proNPQ/spexin are potent central modulators of cardiovascular and renal function and nociception.

Authors:  Lawrence Toll; Taline V Khroyan; Kemal Sonmez; Akihiko Ozawa; Iris Lindberg; Jay P McLaughlin; Shainnel O Eans; Amir A Shahien; Daniel R Kapusta
Journal:  FASEB J       Date:  2011-10-28       Impact factor: 5.191

Review 6.  Most recent developments and modifications of 14-alkylamino and 14-alkoxy-4,5-epoxymorphinan derivatives.

Authors:  L Stavitskaya; A Coop
Journal:  Mini Rev Med Chem       Date:  2011-10       Impact factor: 3.862

7.  Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.

Authors:  Gerta Cami-Kobeci; Willma E Polgar; Taline V Khroyan; Lawrence Toll; Stephen M Husbands
Journal:  J Med Chem       Date:  2011-09-07       Impact factor: 7.446

8.  Unexpected opioid activity profiles of analogues of the novel peptide kappa opioid receptor ligand CJ-15,208.

Authors:  Jane V Aldrich; Santosh S Kulkarni; Sanjeewa N Senadheera; Nicolette C Ross; Kate J Reilley; Shainnel O Eans; Michelle L Ganno; Thomas F Murray; Jay P McLaughlin
Journal:  ChemMedChem       Date:  2011-07-14       Impact factor: 3.466

9.  Multifunctional opioid receptor agonism and antagonism by a novel macrocyclic tetrapeptide prevents reinstatement of morphine-seeking behaviour.

Authors:  Ariana C Brice-Tutt; Lisa L Wilson; Shainnel O Eans; Heather M Stacy; Chloe A Simons; Grant G Simpson; Jeremy S Coleman; Michael J Ferracane; Jane V Aldrich; Jay P McLaughlin
Journal:  Br J Pharmacol       Date:  2020-07-16       Impact factor: 8.739

10.  Alanine analogues of [D-Trp]CJ-15,208: novel opioid activity profiles and prevention of drug- and stress-induced reinstatement of cocaine-seeking behaviour.

Authors:  J V Aldrich; S N Senadheera; N C Ross; K A Reilley; M L Ganno; S E Eans; T F Murray; J P McLaughlin
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.